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Translational Relevance 
 
Triple negative breast cancer (TNBC) represents a molecularly and clinically diverse 
disease with cytotoxic chemotherapy the only systemic treatment modality, and no 
targeted agents approved in adjuvant, neoadjuvant, or metastatic settings. We 
demonstrate that a significant population of aggressive high-grade TNBCs overexpress the 
cell surface tumor-associated antigen Folate Receptor alpha (FRα) and molecules 
involved in folate metabolism. Importantly, FRα is expressed in post-neoadjuvant 
chemotherapy residual disease,  associated with worse clinical outcomes, and participates 
in cancer cell signaling and growth. We show that FRα may present a promising target for 
therapeutic strategies such as antibody-drug conjugates, or antibody immunotherapy that 
primes an Fc-mediated anti-tumor immune response in vitro and in vivo in the human 
patient breast cancer and the patient immune context. Engineering antibodies targeting 
FRα-expressing breast cancers may provide new strategies to treat patients with poor 
prognosis who do not adequately benefit from currently-available targeted, and immuno-
oncology therapies. 
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Abstract 
 
Purpose: Highly-aggressive triple negative breast cancers (TNBCs) lack validated 
therapeutic targets and have high risk of metastatic disease. Folate Receptor alpha (FRα) 
is a central mediator of cell growth regulation that could serve as an important target for 
cancer therapy. 
Experimental Design: We evaluated FRα expression in breast cancers by genomic (N = 
3414) and immunohistochemical (N = 323) analyses and its association with clinical 
parameters and outcomes. We measured the functional contributions of FRα in TNBC 
biology by RNA interference and the anti-tumor functions of an antibody recognizing FRα 
(MOv18-IgG1), in vitro and in human TNBC xenograft models. 
Results: FRα is overexpressed in significant proportions of aggressive basal like/TNBC 
tumors, and in post-neoadjuvant chemotherapy-residual disease associated with a high 
risk of relapse. Expression is associated with worse overall survival. TNBCs show 
dysregulated expression of thymidylate synthase, folate hydrolase 1 and 
methylenetetrahydrofolate reductase, involved in folate metabolism. RNA interference to 
deplete FRα decreased Src and ERK signaling and resulted in reduction of cell growth. An 
anti-FRα antibody (MOv18-IgG1) conjugated with a Src inhibitor significantly restricted 
TNBC xenograft growth. Moreover, MOv18-IgG1 triggered immune-dependent cancer cell 
death in vitro by human volunteer and breast cancer patient immune cells, and significantly 
restricted orthotopic and patient-derived xenograft growth. 
Conclusions: FRα is overexpressed in high-grade TNBC and post-chemotherapy residual 
tumors. It participates in cancer cell signaling and presents a promising target for 
therapeutic strategies such as antibody-drug conjugates, or passive immunotherapy 
priming Fc-mediated anti-tumor immune cell responses. 
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Introduction  
Triple negative breast cancer (TNBC), defined by lack of oestrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) 
expression, represents an urgent unmet clinical need for treatment options. This is largely 
due to its aggressive nature and lack of suitable therapeutic targets. TNBC is a 
heterogeneous disease at the cellular and molecular levels, with its diverse phenotypes 
correlating with different drug resistance and clinical outcomes (1). Gene expression 
profiling and expression signatures have identified five molecularly-distinct types of breast 
cancers, including ER-positive luminal (luminal A and B), HER2-positive, normal-like and 
basal-like (BL) subtypes. The majority of BL carcinomas have a high mitotic rate, and are 
usually triple-negative (2). Different TNBC subgroups also correlate with risk factors, 
incidence, prognosis and treatment response (3). The Lehman-Pietenpol expression 
classification crystallizes six further TNBC subtypes with implications for prediction of 
prognosis and chemotherapy sensitivity (4). Although TNBCs are largely defined by a 
clinical diagnosis of exclusion based on pathological parameters, together these studies 
point to the potential for identification of disease-associated markers which may serve to 
define patient subgroups and lead to personalized targeted therapy. 
At present, no targeted treatments are standard of care for TNBC. Antibodies recognizing 
growth factor receptors such as cetuximab or bevacizumab (5, 6), and small molecule 
drugs such as dovitinib and cabozantinib (7, 8), have been explored in clinical trials, alone 
or in combination with chemotherapy. These have shown relatively limited response rates 
in unselected patient populations (9), most likely due to activation of alternative 
compensatory pathways and inter-/intra-tumoral heterogeneity in expression and 
mutational status, which may be responsible for intrinsic and acquired resistance-driving 
mechanisms (10). Thus, disease management mostly relies on a combination of surgery, 
radiotherapy and multiple chemotherapeutic agents, often associated with high risk of local 
and systemic relapse (11). 
Folate Receptor alpha (FRα) and its ligand folate are central mediators of cell growth 
regulation for the one-carbon metabolic reaction and DNA biosynthesis, repair and 
methylation (12). Insights into FRα distribution (high expression in tumors and restricted 
expression in normal tissues), alongside emerging roles in cancer growth and metastasis 
have led to renewed interest in this as a therapy target (13, 14). Preclinical and clinical 
anti-tumor activities of FRα-targeted therapies have thus far mostly been examined in the 
context of lung and ovarian carcinomas. These include monoclonal antibodies 
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farletuzumab (15) and MOv18-IgG1 (16), antibody-drug conjugate (ADC) Mirvetuximab 
Soravtansine (17), and small molecule drug vintafolide (18). Encouraging results have 
recently been reported for the thymidylate synthase inhibitor ONX-0801 in ovarian 
carcinoma (19). The FRα-targeted hapten immunotherapeutic regimen, Folate Immune, 
was designed to render tumors more immunogenic; however, a phase II trial in renal 
carcinoma was terminated due to low patient accrual (NCT00485563). Another phase I 
trial of a FRα-specific chimeric antigen receptor (CAR)-T cell therapy in ovarian cancer 
patients showed no reduction in tumor burden (20). Recently, Song et al. showed that new 
generation FRα-specific CAR-T cells significantly inhibited high FRα-expressing TNBC 
xenograft growth (21). However, monoclonal antibody therapeutics agents targeting FRα 
are yet untested in TNBC.  
In this study, we examined FRα as a target for monoclonal antibody therapy approaches. 
We ascertained the clinical and biological significance of FRα in TNBC and the largely 
overlapping basal-like subtype, associations of FRα expression with clinical parameters 
and outcomes by genomic and immunohistochemical analyses. We employed RNA 
interference and cell-based functional assays to interrogate how FRα may contribute to 
breast cancer cell biology. We studied FRα and its downstream folate pathway as 
therapeutic targets by assessing the potential anti-tumor functions of an antibody 
recognizing FRα (MOv18-IgG1); as an ADC to inhibit cellular viability in vitro and tumor 
growth in vivo; and as immunotherapy to activate human immune cells against TNBC in 
vitro, in orthotopic and patient-derived tumor xenografts (PDTX) in vivo, more likely able to 
recapitulate the complexity and heterogeneity of human disease (22). Our findings define 
FRα as a promising target for antibody therapies for basal-like breast carcinomas including 
TNBCs. 
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Materials and Methods 
Cell lines 
Cell lines were obtained from King’s College London (KCL) Breast Cancer Now Unit, 
except HDQ-P1, purchased from Leibniz Institute DSMZ. Cell lines were authenticated by 
short tandem repeat profiling. Cells used once tested negative for mycoplasma and used 
up to 30 passages. 
 
Gene expression data of human breast cancers 
The KCL Guy’s Hospital, METABRIC and TCGA Breast cohorts (N=2012) interrogated 
were previously reported (23, 24, 25). Statistical analyses and respective data plots were 
generated in R version 3.2.2. 
 
Tissue microarray (TMA) and immunohistochemistry (IHC) 
Primary breast carcinomas from 305 patients with no prior neoadjuvant therapy, and 18 
surgical specimens from TNBC post-neoadjuvant chemotherapy (post-NACT) residual 
cancer burden II/III residual cases were evaluated. Access to pseudo-anonymized 
samples and clinical data were obtained in accordance with the terms and conditions of 
National Health Service Research Ethics Committee approved Guy’s and St Thomas’ 
Research Tissue and Data Bank (REC No 07/H0804/131). PDTX TMA collection included 
26 TNBC tumors obtained by directly implanting patient material orthotopically into NSG 
mouse mammary fat pads. Staining was performed with FRα IHC Kit (BioCare Medical) 
following manufacturer’s protocol, with additional 30 min anti-FRα incubation 
(API3005AA). IHC with CD45 (Thermo Fisher Scientific) was detected using the DAKO 
EnVision System HRP Kit (peroxidase activity visualized with 3,3-diaminobenzidine). 
Analyses were performed using digital images by NanoZoomer HT Digital Pathology 
Scanning System (Hamamatsu). 
 
siRNA- and lentiviral-mediated RNA interference 
FRα-targeting siRNA sequences and scrambled duplex were purchased from OriGene. 
Transient transfection was performed using Lipofectamine2000 (Thermo Fisher Scientific). 
Viral particles of Tet-pLKO-puro plasmid encoding FRα-specific (5’-
GGATGTTTCCTACCTATATAGATTC), and non-targeting sequence (5’-
GCGCGATAGCGCTAATAATTT) were generated by transfection into 293T cells. CAL51 
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were transduced using 1:30 viral dilution of isolated viral supernatant. Successfully 
transduced clones were selected after 48 hr with 3 μg/ml of puromycin for 5 days, and 1 
μg/ml of doxycycline was used to induce FRα knockdown. 
 
In vitro viability and clonogenic assay 
Cell viabilities were detected by methyl tetrazolium assay (Promega). Optical absorbance 
was read on FLUOstar Omega spectrophotometer (BMG Labtech) to determine viable cell 
counts after 96 hr. For clonogenic assays, cells were fixed by methanol, stained with 
crystal violet solution (Sigma Aldrich). Colonies were measured as a function of mean pixel 
density per well. Image analysis was performed using ImageJ. 
 
Western blot and Human Phospho-Kinase Antibody Array 
Immunoblottings were analyzed with anti-phospho-ERK1/2 (Thr202/Tyr04) (Biolegend) 
and anti-ERK1/2 (Cell Signalling). Proteome Profiler Human Phospho-Kinase Antibody 
Array (R&D Systems) were incubated with 470 μg lysate overnight at 4°C. The following 
day, chemiluminescent detection was done according to manufacturer's protocols. 
Densitometry analysis was performed using ImageJ. 
 
Antibody-drug conjugate production 
MOv18-IgG1 was linked to streptavidin overnight using Lightning-Link Streptavidin 
Conjugation Kit (Expedeon) according to manufacturer’s protocol. A-419259 (Cayman 
Chemical) was biotinylated using EZ-Link-Sulfo-NHS-Biotin (Thermo Fisher Scientific): 10 
mM solution in PBS added to 10 mM EZ-Link-Sulfo-NHS-Biotin in ultrapure water (molar 
ratio 8:1), incubated at room temperature for 30 min, 133 μl of 1.1 mM solution of 
biotinylated A-419259 was added per 1 mg of streptavidin-conjugated MOv18-IgG1, 
followed by 30 min incubation. The ADC was purified by centrifugation using 3K Amicon 
ultra centrifugal filters six times, then resuspended in PBS for functional experiments. 
 
Fluorescence-based tumor cell killing assays 
For live-dead cell cytotoxicity imaging, cancer cells were stained with 5 μM CFSE (Life 
Technologies). The following day, human peripheral blood mononuclear cells (PBMCs) 
were isolated using Ficoll Paque PLUS (GE Healthcare) and stained with CellTracker Blue 
dye (Thermo Fisher Scientific). PBMCs were incubated with cancer cells and MOv18-IgG1 
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or isotype antibody. Ethidium homodimer-1 (4 μM) (Thermo Fisher Scientific) served to 
label dead cells. Samples were imaged using Eclipse Ti-2 inverted microscope equipped 
with Nikon DS-Qi2 sCMOS camera and running NIS Elements. Antibody-dependent cell-
mediated killing of tumor cells was quantified as previously described (26). Data were 
acquired using FACSCanto flow cytometer (BD Biosciences). 
 
In vivo procedures 
Animals were handled in accordance with Institutional Committees on Animal Welfare (The 
Home Office Animals Scientific Procedures Act, 1986). Antibody-drug conjugate: Six-week-
old female CD-1 nude mice were used for orthotopic injection of 1 × 106 CAL51 cells (50 μl 
PBS mixed in 50 μl Matrigel) (day 1). On day 5, mice received single intravenous injection 
of 7.5 mg/kg ADC or MOv18-IgG1, or 5 mg/kg A-419259. Tumors were measured with 
calipers and volumes calculated (π × length × width2 / 6). Experiments were terminated 
after 28 days when tumor sizes were ≤ 525 mm3. Antibody immunotherapy: Female NSG 
mice were orthotopically injected with 1 × 106 CAL51 cells or 0.25 × 106 WHIM02 PDTX 
single cell digests in 50 μl PBS:50 μl Matrigel (day 1). For CAL51, on days 5 and 19, each 
mouse received 12 × 106 human peripheral blood lymphocytes (PBLs) (following red blood 
cell lysis of human blood) intravenously and 5 or 10 mg/kg MOv18-IgG1. Subsequent 
antibody was given once per week. For WHIM02, on days 5 and 18, 12 × 106 human PBLs 
and 10 mg/kg antibody per mouse were given intravenously. Antibody doses were given 
three times in week one and subsequently twice per week. Experiments were terminated 
after 33 days for CAL51 and 20 days for WHIM02, and tumor sizes were ≤ 525 mm3. 
Tumor engraftment of human immune cells was confirmed by IHC staining and flow 
cytometry (antibody panel: rat anti-mouse CD45-V500; mouse anti-human CD45-PE-Cy7, 
CD20-APC, CD3-APC-Cy7, CD68-PE (all BD Biosciences), CD14-PE (eBioscience), 
CD56-PercP Cy5.5 (Cambridge Bioscience). 
 
Statistical analyses 
GraphPad Prism was used for statistical analyses. Data were presented as mean ± 
standard error of the mean (SEM). Differences with P-values < 0.05 were considered 
statistically significant and all tests were two-sided. 
Please see Supplementary Experimental Procedures for more detailed methods.  
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Results  
 
Gene expression pattern of FRα reveal associations with TNBC and basal-like 
breast cancer 
We investigated whether FRα (FOLR1) is expressed in TNBC and its majority basal-like 
subtype by interrogating three transcriptomic datasets: METABRIC (N = 1197) (25), The 
Cancer Genome Atlas (TCGA) (N = 638) (24) and the KCL TNBC-enriched cohort (N = 
177) (23). When tumors were stratified by IHC-defined status, FOLR1 levels were 
significantly higher in TNBC compared with non-TNBC (Fig. 1A). FOLR1 expression was 
also higher in the basal-like molecular subtype defined by PAM50 classification (Fig 1B). 
The small changes of DNA copy number in the genome suggest that copy number had an 
insignificant impact on FOLR1 expression (Supplementary Fig. 1A). FOLR1 was 
expressed in all TNBC subtypes as classified by the Lehman-Pietenpol method 
(Supplementary Fig. 1B). 
Although plasma folate levels have not been clearly associated with breast cancer risk 
(27), low folate status can lead to hypomethylation, subsequent dysregulation of one-
carbon metabolism and DNA instability. This may in turn influence the levels of folate 
receptors or folate carriers (28). However, the association between breast cancer and 
folate status in the tumor microenvironment remains undetermined. We investigated three 
molecules involved in folate metabolism that may be of therapeutic interest in cancer. We 
found that mRNA levels of methylenetetrahydrofolate reductase (MTHFR), a key enzyme 
in the folate metabolic pathway, are significantly decreased in METABRIC and TCGA 
cohorts, although not in the KCL dataset (possibly due to enriched TNBC and low non-
TNBC patient tumor groups). Furthermore, Thymidylate Synthase (TYMS), a folate‐
dependent enzyme involved in the biosynthesis of thymidine for DNA synthesis and repair 
(29), was upregulated in all datasets. There was no significant correlation between FOLR1 
and MTHFR or TYMS expression, suggesting that FRα and folate carriers may be 
independently-regulated in tumors. Notably, expression of folate hydrolase 1 (FOLH1, also 
known as prostate specific membrane antigen (PSMA)), a transmembrane folate 
hydrolase overexpressed in prostate and breast cancers (30), was higher in TNBC/basal-
like subtypes. We found a weak correlation between FOLH1 with FOLR1 expression 
(Pearson’s r = 0.31, p < 0.0005) (Fig. 1C), perhaps suggesting collaborative roles in the 
tumor microenvironment. 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
10 
 
Furthermore, the ten-year overall survival (OS) of patients with high FRα tumor expression 
was significantly lower than those with medium/low expression (Hazard Ratio (HR) = 1.38, 
P = 0.0097) in all breast cancers (N = 1402) (Fig. 1Di). Survival analysis of the TNBC 
patient subset revealed that despite small cohort size (N = 47), high FRα expression 
correlated with decreased OS (HR = 3.35, P = 0.043) (Fig. 1Dii).  
Thus, elevated FRα gene expression and dysregulated expression of molecules involved 
in folate metabolism were detected in basal-like breast carcinomas including TNBCs, and 
FRα expression was associated with worse patient outcomes. 
 
FRα membrane expression by immunohistochemical evaluations 
We next examined FRα expression on a cross-sectional study of breast carcinoma TMA 
specimens (N = 323, of which 76 were TNBCs) (Fig. 2A). In contrast to a restricted 
distribution pattern in normal tissues (31), high frequency (>70%) FRα protein expression 
correlated with high grade disease (Grade I: 0.0%; II: 7.7%; III: 24.7%). Three quarters of 
the FRα-positive grade III samples displayed a medium (41-70%) or a high (71-100%) 
percentage of cancer cells with membrane FRα immunostaining. Expression was less 
frequently-associated with ER-positive (7.5%), HER2 (15.6%) or luminal (6.5%) tumors, 
relative to ER-negative tumors (30.0%) and TNBC (36.8%) (by IHC classification). FRα 
expression in TNBCs vary among studies, from 20% (32) to 67% or 80% positivity (33, 
34). According to PAM50 molecular classification, we observed FRα expression in 10.7% 
of HER2-positive and 7.1% of luminal A cancers, while FRα expression was more common 
in basal-like subtypes (33.3%) (Supplementary Table 1) in concordance with a recent 
report (32). Furthermore, cell membrane FRα immunostaining, significantly correlated with 
mRNA expression in the same patient samples (P < 0.0005) (Fig. 2B). We also found that 
13% of samples negative for membrane FRα demonstrated cytoplasmic, non-membrane, 
FRα staining; these tissues may not be amenable to anti-FRα antibody treatment. 
Due to lack of effective targetable oncogenic drivers, treatment for TNBC commonly 
involves cytotoxic chemotherapy, often given prior to surgery. A subpopulation of 
chemotherapy-resistant residual tumor cells remaining in breast tissue may be responsible 
for high metastatic recurrence rates and poor long-term clinical outcomes (35, 36). In a 
TMA containing eighteen TNBC samples from patients with residual disease post-NACT, 
we found FRα expression in 61.1% of residual tumors (Fig. 2C), and >75% of positive 
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samples displayed medium or high percentage of cells with membrane FRα 
immunostaining.  
In summary, more TNBC specimens have FRα-positive immunostaining than other breast 
cancer subtypes. This is particularly marked in post-NACT residual disease, suggesting 
that FRα could be therapeutically targeted. 
 
FRα expression contributes to breast cancer growth 
To gain insights into FRα functions, we evaluated FRα expression in twenty-two breast 
cancer cell lines by flow cytometry using the monoclonal antibody MOv18-IgG1 (Fig. 3A, 
Supplementary Fig. 2A-C). Protein expression correlated with transcriptomic expression 
(Cancer Cell Line Encyclopedia (CCLE)) (Spearman's rank coefficient, r = 0.5784, P < 
0.01, Fig. 3B). Three cell lines (CAL51, T47D and HDQ-P1) showed the highest levels of 
FRα expression by mRNA and corresponding cell surface expression. 
Traditionally FRα has been viewed as an intracellular transporter of soluble folate. 
However, recent findings indicate that FRα may form macromolecular complexes in which 
it may contribute to upregulation of oncogenic STAT3/JAK pathways (37) and Lyn signaling 
(38). We therefore hypothesized that FRα expression may confer a proliferative advantage 
to high-expressing tumors. Employing RNA interference, we found that FRα expression 
(mean fluorescence intensity, MFI) in cells treated with FRα-targeting siRNA (siFRα) was 
significantly lower than in those treated with non-targeting siRNA (siNT) (Supplementary 
Fig. 2D). Reduction in FRα was accompanied by reduced cell viability compared with 
scrambled siRNA-treated cells (Fig. 3C, Supplementary Fig. 2E). FRα knockdown also 
resulted in reduction of colony formation (Fig. 3C, Supplementary Fig. 2F). Neither viability 
nor colony formation were affected by FRα knockdown in low FRα-expressing MDA-MB-
231 cells. 
To further interrogate the contribution of FRα to breast cancer biology, we created a stable, 
doxycycline-inducible, FRα-knockdown CAL51 cell line. The resulting shRNA-transduced 
cells had a four-fold lower mean relative FRα expression measured by flow cytometry 
when compared with cells transduced with non-targeting sequence (shNT). In 
concordance with siRNA experiments, FRα knockdown led to a modest reduction in 
proliferation (to 75.9 ± 2.2% viability (% ± SEM: P < 0.0005), and reduced colony formation 
ability (to 65.8 ± 23.1%, P < 0.05). Furthermore, consistent with proposed roles in 
downstream oncogenic signaling pathways such as STAT3/JAK, we measured a 
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significant decrease in phosphorylated ERK activity to 30.4 ± 7.2% (P < 0.0005) with FRα 
knockdown, suggesting reduction of another proliferative signaling pathway (Fig. 3D, 
Supplementary Fig. 3A).  
Furthermore, we studied the anti-tumor effects of raltitrexed, a highly-selective inhibitor of 
thymidylate synthase, the key enzyme in folate metabolism (Fig. 1). CAL51 shNT cells 
(with high FRα expression levels) were more sensitive to raltitrexed compared to FRα-
knockdown cells in both normal or folate-free conditions (Fig. 3E).  
Together, these data indicate that FRα plays key roles in cell growth and TNBC may be 
sensitive to therapeutic treatment targeting the folate cycle. 
 
FRα-dependent signaling functions in breast cancer cells 
We sought to interrogate the molecular signaling processes regulated by FRα and explore 
the development of targeted therapeutic options. Signaling pathways were assessed using 
a human phosphokinase array studied in shNT- and shFRα-transduced CAL51 (Fig. 4A). 
FRα knockdown significantly decreased the activity of several members of the Src-family 
non-receptor tyrosine kinase, Lyn, Fyn, Hck and Src, their downstream effector molecule 
ERK, and of the anti-apoptotic protein CREB. Moreover, FRα silencing was associated 
with increased activity of the metabolic regulator AMPKa1 and the cell cycle regulator p53 
(S15 and S392), when compared with control shRNA treatment. 
Growth inhibition by the broad spectrum Src-family kinase inhibitor A-419259 was 
observed in cell lines with high FRα expression, but not with MDA-MB-231 which express 
near background levels of FRα (Fig. 4B). Growth inhibition was also demonstrated in 
CAL51 using a second Src-family kinase inhibitor AZM475271 (Supplementary Fig. 3C). 
The A-419259 inhibitor (50nM) also significantly reduced colony formation to 31.2 ± 4% (P 
< 0.0005) and ERK activation to 54.6 ± 9.2% (P < 0.005) (Fig. 4B). 
These data suggest that FRα is upstream of multiple Src-family kinases and ERK (Fig. 
4C), known to be involved in breast cancer biology, and identify FRα as cell surface 
molecule associated with signaling and growth, with potential to be targeted in therapeutic 
strategies for TNBC. 
The anti-FRα antibody MOv18-IgG1 exerted a very modest direct inhibition in cell viability 
under folate-reduced conditions (0.4nM folate) (remaining viability: 86.3 ± 2.5%, P < 0.05 
for 10 µg/ml; 87.5 ± 0.9%, P < 0.005 for 50 µg/ml), when compared with media alone 
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controls (Supplementary Fig. 3D). This suggested that any direct anti-tumor effects of 
these agents may be limited to folate-depleted environments, perhaps akin to conditions 
found in tumors. 
MOv18-IgG1 did not engender significant direct inhibition of FRα-dependent signaling 
under physiological conditions. We therefore developed a FRα-targeting antibody-coupled 
inhibitor ADC strategy by conjugating the Src-family kinase inhibitor A-419259 to MOv18-
IgG1, using the antibody as a vehicle to specifically deliver the inhibitor to cancer cells. 
Cell viability assessments resulted in significantly-lower IC50 dose for ADC (0.47 nM) 
compared with inhibitor alone treatment (>50 nM) (Fig. 4D). In CAL51 xenografts, ADC or 
A-419259 treatment resulted in significantly-reduced tumor growth and tumor weights 
compared with antibody alone or vehicle controls. ADC resulted in significantly-lower tumor 
weights (14.7 ± 1.4, mg ± SEM) compared with vehicle (32.5 ± 2.4 mg, P < 0.0005) or 
antibody (39.4 ± 8.8 mg, P < 0.005) treatments. Tumor weights after inhibitor treatment 
(19.9 ± 5.0 mg) were significantly-lower than antibody or vehicle controls (P < 0.05). ADC 
(7.5 mg/kg, equivalent to 2.66 μg A-419259 per mouse) and inhibitor alone (5 mg/kg, 
equivalent to 0.1 mg A-419259 per mouse) showed similar growth inhibition, although the 
A-419259 dose coupled with ADC measured only 2.66% of the dose of uncoupled inhibitor 
(Fig. 4E). 
Our findings demonstrate the therapeutic potential of ADC targeting FRα and downstream 
pathways against breast cancer. 
 
MOv18-IgG1 induces tumor cell killing by human immune cells 
We next evaluated the potential of MOv18-IgG1 to activate immune effector cells against 
cancer cells. In a live-dead cell cytotoxicity imaging assay, human PBMCs pre-labeled with 
CellTracker Blue dye served as immune effector cells, and CFSE-labelled CAL51 were 
used as targets. We observed higher rates of dead cells (red fluorescent cells, depicting 
ethidium homodimer-1 incorporation into dead cells) with MOv18-IgG1 compared with 
control antibody treatments (Fig. 5A). We quantified tumor cell killing (Antibody-Dependent 
Cell-mediated Cytotoxicity (ADCC) and Phagocytosis (ADCP)) by MOv18-IgG1 using a 
flow cytometry-based assay (26). With U937 human monocytes as effector cells 
(Supplementary Fig. 4A), MOv18-IgG1 mediated killing of FRα-expressing, but not of low 
FRα-expressing cancer cells by a combination of ADCC and ADCP functions (Fig. 5B; 
Supplementary Fig. 4C). MOv18-IgG1 induced predominantly ADCP effects (ADCC vs 
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ADCP ratios: CAL51 = 1.6:1, T47D = 0.4:1, HDQ-P1 = 0.5:1). These effector functions are 
consistent with previously-reported tumor cell killing engendered by human monocytes and 
tumor antigen-specific IgG1 antibodies (26, 39). 
Breast cancer patients’ immune responses may be suppressed, and patient immune 
profiles may be altered by adjuvant radiotherapy or chemotherapy (40), hence potentially 
less capable of restricting tumor growth. MOv18-IgG1 could stimulate immune effector 
cells (PBMC) from healthy volunteers and patients with TNBC (patient characteristics: 
Supplementary Fig. 4D) to kill CAL51 in an antigen-specific manner (ADCC vs ADCP ratio: 
healthy volunteers 0.8:1; TNBC patients 0.7:1) (Fig. 5C, Supplementary Fig. 4E and 4F). 
These data demonstrate the ability of an anti-FRα antibody to activate patient immune 
effector cells to induce breast cancer cell death in vitro. 
 
Anti-FRα antibody treatment restricts the growth of two orthotopic TNBC human 
xenograft tumors in vivo 
We examined the potential Fc-mediated anti-tumor effects of MOv18-IgG1 in vivo. We 
employed an orthotopic mammary fat pad-established human TNBC xenograft in 
immunodeficient mice. This model features impairments in B, T and natural killer (NK) cell 
development and functions, and lack MHC class I/II expression, designed to minimize the 
xenogeneic graft-versus-host disease. The model allows introduction of human immune 
cells to serve as human FcR-expressing effector cells (41), therefore, treatments followed 
introduction of immune effector cells (freshly-isolated human PBL). 
Immunohistochemical evaluations of established xenografts confirmed in situ FRα 
expression in mammary orthotopically-formed CAL51 tumors (Fig. 6A). Tumors from mice 
given PBL showed human immune cell (CD45+) infiltration in immunohistochemical 
evaluations (Fig. 6B), confirmed by flow cytometric assessments of human CD45+ cells 
extracted from xenografts. MOv18-IgG1-treated animals at either 5 or 10 mg/kg dosages 
showed significantly reduced tumor growth and resected tumor weights (Fig. 6C) 
compared with controls. Average tumor weight was 90 ± 20 (mg ± SEM) for the 5 mg/kg 
group and 60 ± 10 mg for the 10 mg/kg group, compared to control mice given PBS (150 ± 
20 mg, P < 0.05), PBL-alone (120 ± 10 mg, P < 0.005) or antibody-alone (170 ± 20 mg, P 
< 0.005). 
We investigated whether the antibody treatment could also restrict TNBC PDTX growth. 
Immunohistochemical evaluations revealed that 11 of 26 (46.2%) PDTX tumors were FRα 
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positive (Fig. 6D). We examined the efficacy of MOv18-IgG1 in the fast-growing WHIM02 
PDTX model that features high (100% of cells) membrane FRα expression. All WHIM02 
tumors injected with PBL showed immune cell infiltration in tumor stroma irrespective of 
treatment (Fig. 6E). Average tumor weight was 350 ± 40 mg in PBL-alone group compared 
to 100 ± 20 mg with MOv18-IgG1 treatment (71% lower average tumor weight, P < 
0.0005), suggesting significantly-reduced growth associated with antibody treatment. 
Although the great proportion of infiltrating CD45+ human cells were T cells 
(Supplementary Fig. 5), we measured a modest increase in tumor-infiltrating macrophages 
(3.8 ± 0.9% with MOv18-IgG1, compared to 1.2 ± 0.5% PBS, P < 0.05) and NK cells (5.7 ± 
1.5% with MOv18-IgG1, compared to 1.7± 0.5% PBS, P < 0.05) (Fig. 6G) associated with 
antibody treatment. This is consistent with the immune activation seen in vitro. 
Our results therefore demonstrate significant tumor growth restriction associated with anti-
FRα antibody in both orthotopic TNBC line and PTDX models. These effects may at least 
partly be attributed to a responsive, antibody-dependent, immune effector cell mechanism, 
a notion supported by MOv18-IgG1-mediated tumor/immune cell interactions and 
ADCC/ADCP functions against cancer cells.  
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
16 
 
Discussion 
Cytotoxic chemotherapy remains the only systemic treatment modality for patients with 
TNBC, partly because tumor-associated molecules amenable to targeted therapies 
including antibodies need to be identified and validated. Our genomic and 
immunohistochemical evaluations demonstrate that a significant population of TNBCs, 
including viable post-neoadjuvant chemotherapy residual disease, are likely to 
overexpress the tumor-associated antigen FRα, and that this antigen participates in the 
biological functions of breast cancer cells. We show that monoclonal antibody approaches 
recognizing FRα can offer treatment strategies against TNBC, such as through the design 
of an antibody conjugate to specifically deliver a signaling blocking agent (Fig. 4). 
Avoiding immune destruction is considered a hallmark of cancer (42), yet recent 
breakthroughs demonstrate that the immune system can play important roles in controlling 
malignant disease, and that antibodies can provide a means by which immune cells could 
be directed against cancer. For example, treatment with anti-PD-1 inhibitor antibody 
pembrolizumab could confer clinical responses in 18.5% of patients with advanced TNBC 
pre-screened for expression of the ligand PD-L1 in tumors [NCT01848834] (43). 
Antibodies such as our anti-FRα clone, can also engender immune-mediated cancer cell 
killing via engagement of Fc receptors-expressing effector cells (monocytes, 
macrophages, NK cells). We exemplify these properties using patient immune effector 
cells in vitro and in orthotopic and patient-derived TNBC models in vivo (Fig. 5-6). 
Design of anti-tumor antibodies requires selection of a target, ideally one overexpressed 
by cancer cells and possibly associated with engendering biological advantages to cancer. 
This may permit selective recognition of more aggressive cancer cells and may facilitate 
their destruction by targeted treatments, or engagement and activation of effector cells in 
the immune stroma. We provide evidence to support further evaluation of FRα as a 
promising target for treatment of a subset of breast cancers. We report that high FRα 
expression and dysregulated folate metabolic pathway may be associated with basal-
like/TNBC phenotype. Importantly, FRα is expressed in high-risk high-grade disease and in 
post-neoadjuvant chemotherapy residual tumors, themselves associated with high 
metastatic relapse. Targeted therapies centered on FRα may also benefit from reported 
low and restricted FRα expression to a small subset of non-malignant tissues (44). We 
demonstrate that FRα expression confers proliferative and clonogenic advantages to 
tumor cells and contributes to pathway activation of Src-family non-receptor tyrosine 
kinases. FRα expression has been shown to associate with STAT3/JAK signaling before 
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(37), and, here in this report, to contribute to cancer cell signaling through the Src/ERK 
pathway. These insights point to new opportunities for targeting FRα and for disrupting its 
associated signaling cascades using a specific inhibitor (Fig. 3-4). 
We demonstrate that FRα-expressing cells can be subjected to human volunteer and 
TNBC patient-derived immune cell-mediated killing with MOv18-IgG1. These effects were 
not seen against low FRα-expressing cells, suggesting potentially low or no on-target/off-
tumor toxic effects. Lowly-expressing normal tissues, mostly rely on other routes of folate 
uptake, namely the reduced folate carrier or proton-coupled folate transporter. The ability 
of this antibody to induce ADCP/ADCC against cancer cells in an antigen-dependent 
manner supports continued study of this and potentially other antibody strategies as 
passive immunotherapies for breast tumors. Our investigations of therapeutic efficacy in 
orthotopic xenografts showed significant reduction in tumor growth in both TNBC line and 
PDTX tumors. Additionally, PDTX studies revealed an increase in tumor-infiltrating 
macrophages and NK cells associated with anti-FRα antibody treatment. This may suggest 
that targeted therapy with antibodies could present an opportunity to influence the immune 
stroma, enhance cancer cell recognition by effector cells and ultimately activate these cells 
to control tumor growth (45, 46). Our findings point to a functionally-active antibody able to 
prime an anti-tumor immune response that is potentially relevant and translatable to the 
human cancer setting. 
Despite their aggressive clinical behavior, TNBCs tend to initially respond better to 
neoadjuvant chemotherapy compared with other breast cancer types (47). Furthermore, 
chemotherapeutic agents may have immunomodulatory activity within the tumor 
microenvironment, supporting the presence of tumor-infiltrating lymphocytes (48). 
However, five-year survival rates remain significantly worse in TNBC than in non-TNBC 
patients, likely driven by chemotherapy-resistant cells, possibly residing in micro-
metastatic sites that subsequently lead to lethal clinical recurrence (35). We detected FRα-
positive tumors in post-neoadjuvant treated residual TNBCs. As residual TNBCs that 
contain low densities of tumor-infiltrating immune cells after neoadjuvant chemotherapy 
have a higher risk of relapse (49), FRα-targeting antibody may present a potential strategy 
to retain or recruit immune effector cells in tumor stroma. 
Past and ongoing clinical evaluations of FRα-targeted therapies and monoclonal 
antibodies, provide ground for cautious optimism. Vintafolide (MK-8109/EC145) is being 
evaluated in a phase III trial for ovarian cancer [NCT01170650] and a phase IIb trial for 
non-small cell lung cancer [NCT01577654]. A phase II trial of vintafolide in FRα-positive 
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TNBC is expected. The concept of using FRα-specific anti-folate drugs is evaluated in an 
early phase I trial of the first-in-class thymidylate synthase inhibitor, ONX-0801, in solid 
tumors [NCT02360345] (19). Furthermore, with the same specificity for an epitope of FRα, 
the MOv18-IgE isotype is being evaluated in a first-in-class clinical trial for ovarian cancer 
[NCT02546921] (50). Clinical experience with these agents points to a need for improved 
patient selection and for elucidating mechanisms of action. In breast cancer, FRα 
expression levels could be used for patient stratification. Perhaps tumor infiltration of key 
effector cells that may be activated against highly-aggressive or chemotherapy-resistant 
cancer cells, could also be employed to monitor treatment responses or to select patients 
more likely to benefit. 
Collectively, our findings support FRα expression at the transcriptomic and protein levels, 
and cell surface expression in a proportion of basal-like and TNBC subtypes, including in 
neoadjuvant chemotherapy-resistant tumors. We report associations of higher expression 
with worse clinical outcomes, and evidence for functional significance in breast cancer cell 
biology. We demonstrate the potential tumor-restricting effects of anti-FRα MOv18-IgG1; 
by potentiating immune effector cell activation and cancer cell-neutralizing functions in 
vitro and by restricting tumor growth in orthotopic TNBC line and PDTX models in vivo; by 
an ADC design approach of the anti-FRα antibody coupled with a Src-family kinase 
inhibitor in vitro and in vivo. Our findings point to FRα as a promising antigen for different 
antibody therapy approaches and may provide the basis for further translational 
investigations, effective patient stratification and personalized therapies, especially for 
patients who do not adequately benefit from currently-available treatments. 
 
  
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
19 
 
Acknowledgments 
Patient tissue samples were provided by King’s Heath Partners Cancer Biobank, London, 
UK, which is supported by the Department of Health via the National Institute for Health 
Research comprehensive Biomedical Research Centre award. We acknowledge the 
Biomedical Research Centre Immune Monitoring Core Facility team at Guy’s and St 
Thomas' NHS Foundation Trust and the Nikon Imaging Centre at Kings College London for 
assistance. The authors acknowledge support by Breast Cancer Now (147), working in 
partnership with Walk the Walk; Cancer Research UK (C30122/A11527; C30122/A15774); 
the Medical Research Council (MR/L023091/1); the Academy of Medical Sciences; CR 
UK//NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer 
Medicine Centre (C10355/A15587). The research was supported by the National Institute 
for Health Research Biomedical Research Centre based at Guy's and St Thomas' NHS 
Foundation Trust and King's College London (IS-BRC-1215-20006). 
 
  
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
20 
 
References 
1. Lehmann, B.D., Pietenpol, J.A. and Tan, A.R. Triple-negative breast cancer: molecular 
subtypes and new targets for therapy. Am Soc Clin Oncol Educ Book 2015: e31-39. 
2. Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., et al. 
Molecular portraits of human breast tumours. Nature 2000;  406: 747-752. 
3. Diaz, L.K., Cryns, V.L., Symmans, F. and Sneige, N. Triple negative breast carcinoma and 
the basal phenotype: From expression profiling to clinical practice. Advances in Anatomic 
Pathology 2007;  14: 419-430. 
4. Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, Y., et al. 
Identification of human triple-negative breast cancer subtypes and preclinical models for 
selection of targeted therapies. J Clin Invest 2011;  121: 2750-2767. 
5. Baselga, J., Gomez, P., Greil, R., Braga, S., Climent, M.A., Wardley, A.M., et al. 
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal 
antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-
negative breast cancer. J Clin Oncol 2013;  31: 2586-2592. 
6. Cameron, D., Brown, J., Dent, R., Jackisch, C., Mackey, J., Pivot, X., et al. Adjuvant 
bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary 
results of a randomised, phase 3 trial. Lancet Oncol 2013;  14: 933-942. 
7. Tolaney, S.M., Nechushtan, H., Ron, I.G., Schoffski, P., Awada, A., Yasenchak, C.A., et al. 
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled 
randomized discontinuation study. Breast Cancer Res Treat 2016;  160: 305-312. 
8. Andre, F., Bachelot, T.D., Campone, M., Dalenc, F., Perez-Garcia, J.M., Hurvitz, S.A., et al. 
A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 
(FGFR1) inhibitor, in FGFR1-amplified and nonamplified metastatic breast cancer (BC). J 
Clin Oncol 2011;  29: 289. 
9. Arrowsmith, J. and Miller, P. Trial watch: phase II and phase III attrition rates 2011-2012. 
Nat Rev Drug Discov 2013;  12: 569. 
10. Hopper-Borge, E.A., Nasto, R.E., Ratushny, V., Weiner, L.M., Golemis, E.A. and Astsaturov, 
I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 
2009;  13: 339-362. 
11. Gucalp, A. and Traina, T.A. Triple-negative breast cancer: adjuvant therapeutic options. 
Chemother Res Pract 2011;  2011: 696208. 
12. Locasale, J.W. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat 
Rev Cancer 2013;  13: 572-583. 
13. Cheung, A., Bax, H.J., Josephs, D.H., Ilieva, K.M., Pellizzari, G., Opzoomer, J., et al. 
Targeting folate receptor alpha for cancer treatment. Oncotarget 2016;  7: 52553-52574. 
14. Hartmann, L.C., Keeney, G.L., Lingle, W.L., Christianson, T.J., Varghese, B., Hillman, D., et 
al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J 
Cancer 2007;  121: 938-942. 
15. Vergote, I., Armstrong, D., Scambia, G., Teneriello, M., Sehouli, J., Schweizer, C., et al. A 
Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and 
Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients 
With Ovarian Cancer in First Platinum-Sensitive Relapse. J Clin Oncol 2016;  34: 2271-
2278. 
16. van Zanten-Przybysz, I., Molthoff, C., Gebbinck, J.K., von Mensdorff-Pouilly, S., 
Verstraeten, R., Kenemans, P., et al. Cellular and humoral responses after multiple injections 
of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot 
study. J Cancer Res Clin Oncol 2002;  128: 484-492. 
17. Moore, K.N., Martin, L.P., O'Malley, D.M., Matulonis, U.A., Konner, J.A., Perez, R.P., et al. 
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
21 
 
Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or 
Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol 2017;  35: 1112-1118. 
18. Luyckx, M., Votino, R., Squifflet, J.L. and Baurain, J.F. Profile of vintafolide (EC145) and 
its use in the treatment of platinum-resistant ovarian cancer. Int J Womens Health 2014;  6: 
351-358. 
19. Tochowicz, A., Dalziel, S., Eidam, O., O'Connell, J.D., 3rd, Griner, S., Finer-Moore, J.S., et 
al. Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-
tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta [g]quinazolin-6-yl]amino]benzoyl]-l-
gamma-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that 
targets tumor cells. J Med Chem 2013;  56: 5446-5455. 
20. Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., et 
al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian 
cancer. Clin Cancer Res 2006;  12: 6106-6115. 
21. Song, D.G., Ye, Q., Poussin, M., Chacon, J.A., Figini, M. and Powell, D.J., Jr. Effective 
adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected 
CAR T cells is influenced by surface antigen expression level. J Hematol Oncol 2016;  9: 
56. 
22. DeRose, Y.S., Wang, G., Lin, Y.C., Bernard, P.S., Buys, S.S., Ebbert, M.T., et al. Tumor 
grafts derived from women with breast cancer authentically reflect tumor pathology, growth, 
metastasis and disease outcomes. Nat Med 2011;  17: 1514-1520. 
23. Gazinska, P., Grigoriadis, A., Brown, J.P., Millis, R.R., Mera, A., Gillett, C.E., et al. 
Comparison of basal-like triple-negative breast cancer defined by morphology, 
immunohistochemistry and transcriptional profiles. Mod Pathol 2013;  26: 955-966. 
24. The.Cancer.Genome.Atlas.Network. Comprehensive molecular portraits of human breast 
tumours. Nature 2012;  490: 61-70. 
25. Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., et al. The 
genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. 
Nature 2012;  486: 346-352. 
26. Bracher, M., Gould, H.J., Sutton, B.J., Dombrowicz, D. and Karagiannis, S.N. Three-colour 
flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity 
and phagocytosis. J Immunol Methods 2007;  323: 160-171. 
27. Matejcic, M., de Batlle, J., Ricci, C., Biessy, C., Perrier, F., Huybrechts, I., et al. Biomarkers 
of folate and vitamin B12 and breast cancer risk: report from the EPIC cohort. Int J Cancer 
2017;  140: 1246-1259. 
28. Song, M.A., Brasky, T.M., Marian, C., Weng, D.Y., Taslim, C., Llanos, A.A., et al. Genetic 
variation in one-carbon metabolism in relation to genome-wide DNA methylation in breast 
tissue from heathy women. Carcinogenesis 2016;  37: 471-480. 
29. Rustum, Y.M., Harstrick, A., Cao, S., Vanhoefer, U., Yin, M.B., Wilke, H., et al. 
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin 
Oncol 1997;  15: 389-400. 
30. Kasoha, M., Unger, C., Solomayer, E.F., Bohle, R.M., Zaharia, C., Khreich, F., et al. 
Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases. 
Clin Exp Metastasis 2018. 
31. Sega, E.I. and Low, P.S. Tumor detection using folate receptor-targeted imaging agents. 
Cancer Metastasis Rev 2008;  27: 655-664. 
32. Ginter, P.S., McIntire, P.J., Cui, X., Irshaid, L., Liu, Y., Chen, Z., et al. Folate Receptor 
Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast 
Cancer. Clin Breast Cancer 2017;  17: 544-549. 
33. Zhang, Z., Wang, J., Tacha, D.E., Li, P., Bremer, R.E., Chen, H., et al. Folate receptor alpha 
associated with triple-negative breast cancer and poor prognosis. Arch Pathol Lab Med 
2014;  138: 890-895. 
34. O'Shannessy, D.J., Somers, E.B., Maltzman, J., Smale, R. and Fu, Y.S. Folate receptor alpha 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
22 
 
(FRA) expression in breast cancer: identification of a new molecular subtype and 
association with triple negative disease. Springerplus 2012;  1: 22. 
35. Balko, J.M., Giltnane, J.M., Wang, K., Schwarz, L.J., Young, C.D., Cook, R.S., et al. 
Molecular profiling of the residual disease of triple-negative breast cancers after 
neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2014;  4: 
232-245. 
36. Symmans, W.F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M., et al. Long-Term Prognostic 
Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast 
Cancer Subtype. J Clin Oncol 2017;  35: 1049-1060. 
37. Hansen, M.F., Greibe, E., Skovbjerg, S., Rohde, S., Kristensen, A.C., Jensen, T.R., et al. 
Folic acid mediates activation of the pro-oncogene STAT3 via the Folate Receptor alpha. 
Cell Signal 2015;  27: 1356-1368. 
38. Miotti, S., Bagnoli, M., Tomassetti, A., Colnaghi, M.I. and Canevari, S. Interaction of folate 
receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes 
from the ovary carcinoma cell line IGROV1. J Cell Sci 2000;  113 Pt 2: 349-357. 
39. Hayes, J.M., Wormald, M.R., Rudd, P.M. and Davey, G.P. Fc gamma receptors: 
glycobiology and therapeutic prospects. J Inflamm Res 2016;  9: 209-219. 
40. Mozaffari, F., Lindemalm, C., Choudhury, A., Granstam-Bjorneklett, H., Lekander, M., 
Nilsson, B., et al. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, 
epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study. 
Cancer Immunol Immunother 2009;  58: 111-120. 
41. Karagiannis, P., Gilbert, A.E., Josephs, D.H., Ali, N., Dodev, T., Saul, L., et al. IgG4 
subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 2013;  123: 
1457-1474. 
42. Hanahan, D. and Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 2011;  144: 
646-674. 
43. Nanda, R., Chow, L.Q., Dees, E.C., Berger, R., Gupta, S., Geva, R., et al. Pembrolizumab in 
Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J 
Clin Oncol 2016;  34: 2460-2467. 
44. Kelemen, L.E. The role of folate receptor alpha in cancer development, progression and 
treatment: cause, consequence or innocent bystander? Int J Cancer 2006;  119: 243-250. 
45. Cantoni, C., Huergo-Zapico, L., Parodi, M., Pedrazzi, M., Mingari, M.C., Moretta, A., et al. 
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints 
for NK-Based Immunotherapy? J Immunol Res 2016;  2016: 4684268. 
46. Williams, C.B., Yeh, E.S. and Soloff, A.C. Tumor-associated macrophages: unwitting 
accomplices in breast cancer malignancy. NPJ Breast Cancer 2016;  2.: pii: 15025. 
47. Denkert, C., von Minckwitz, G., Brase, J.C., Sinn, B.V., Gade, S., Kronenwett, R., et al. 
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without 
carboplatin in human epidermal growth factor receptor 2-positive and triple-negative 
primary breast cancers. J Clin Oncol 2015;  33: 983-991. 
48. Garcia-Martinez, E., Gil, G.L., Benito, A.C., Gonzalez-Billalabeitia, E., Conesa, M.A., 
Garcia Garcia, T., et al. Tumor-infiltrating immune cell profiles and their change after 
neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer 
Res 2014;  16: 488. 
49. Dieci, M.V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., et al. Prognostic 
value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for 
triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 2014;  25: 611-
618. 
50. Josephs, D.H., Bax, H.J., Dodev, T., Georgouli, M., Nakamura, M., Pellizzari, G., et al. Anti-
Folate Receptor-alpha IgE but not IgG Recruits Macrophages to Attack Tumors via 
TNFalpha/MCP-1 Signaling. Cancer Res 2017;  77: 1127-1141.  
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
23 
 
 
 
 
 
Figure legends 
 
Figure 1. Basal-like/TNBC is associated with upregulated FRα gene expression 
Gene expression in METABRIC, TCGA and KCL datasets for FOLR1, MTHFR, TYMS and 
FOLH1. (A) Cohorts were divided into TNBC and non-TNBC based on IHC-defined 
receptor status. (B) Cohorts above were stratified according to PAM50 classification 
(Basal-like (Basal), HER2, luminal A (L.A), luminal B (L.B) and normal-like (N.L.)). Median-
centered gene expression log2 values are shown. Numbers of patients per group is 
indicated below the graphs in the first column. P-values were determined using the 
Wilcoxon rank-sum test. (C) Relationship between FOLR1 and FOLH1 in the KCL dataset. 
(D) Association of FRα expression (upper quartile) with ten-year overall survival. (i) 
Kaplan-Meier curves in 1,402 breast cancer samples, and (ii) TNBC subset with 47 
samples. The number of patients per group is indicated below. Significant P-values are 
indicated with an asterisk, where * P < 0.05; ** P < 0.005; *** P < 0.0005. 
 
Figure 2. FRα expression is associated with high grade breast cancer and basal-
like/TNBC, and is found in chemotherapy-resistant residual TNBC tumors. 
(A) IHC staining for FRα membrane expression in KCL TMA. Representative images 
showing restricted expression in normal human kidney and lung sections, (i) a case with 
no FRα expression and negative staining, (ii-v) positive cell surface cancer cell FRα 
staining, score: 10% to 100%. Data were classified based on tumor grade and IHC- or 
PAM50-defined receptor status. Each group with the highest population of positive cancer 
cell surface staining were displayed in pie chart subdivided into three sectors (low, medium 
and high score based on % membrane FRα staining). (B) Microarray-based FRα mRNA 
expression were compared to membrane FRα staining positivity tested by IHC staining. 
(C) IHC staining for membrane FRα expression in KCL post-neoadjuvant chemotherapy 
residual TNBC tumor TMA. (i-iv) Representative images showing FRα staining, score: 0% 
to 100%. 11 out of 18 samples were found to be positive for FRα expression. Pie chart 
subdivided the samples into three sectors (low, medium and high score based on % of 
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cells positive for membrane FRα staining). The proportion of patients per group is 
indicated below. Significant P-value is indicated with an asterisk where *** P < 0.0005. 
 
Figure 3. Surface FRα protein levels in breast cancer cell lines and RNA interference 
of FRα leads to reduction in cellular activities 
(A) Surface FRα expression of twenty-two breast cancer cell lines were evaluated by flow 
cytometry using MOv18-IgG1. Histopathological subtype of each cell line was listed on 
Supplementary Fig. 2A. Cell lines with high surface FRα level that were ultimately selected 
for further analysis are highlighted (CAL51, red; T47D, blue; HDQ-P1, pink, also see 
representative histograms of flow cytometric evaluations of FRα expression). The 
evaluations also included the widely studied breast cancer surface receptors EGFR and 
HER2 as internal controls (Supplementary Fig. 2B and 2C). (B) FRα mRNA expression 
data of the cell lines were extracted from CCLE database. Analyses showed a positive 
correlation (r = 0.5784) between protein and mRNA levels of expression (Spearman's 
Rank coefficient analysis, P < 0.01). (C) Significant restrictions in cellular growth after 96 hr 
of siRNA-mediated silencing of FRα, and reduction in colony density over a ten-day period, 
were shown only in the FRα-positive cell lines. (D) FRα expression in CAL51 cells 
transduced with non-targeting shRNA (shNT) and FRα-targeting shRNA (shFRα) were 
represented as MFI based on MOv18-IgG1 staining. CAL51 demonstrated growth 
restriction, visible reduction in colony density, and decreased ERK activity with stable FRα 
knockdown. (E) Parental CAL51 were treated with raltitrexed in both normal and folate-free 
conditions. Cells with FRα knockdown were less sensitive to the treatment in both 
conditions. The data represent the mean ± SEM values of at least three independent 
experiments. * P < 0.05; ** P < 0.005; *** P < 0.0005, by two-tailed unpaired t-test. 
 
Figure 4. FRα modulates phosphorylation of targetable signaling molecules and 
antibody-drug conjugate inhibition of tumor growth. 
(A) Images from Proteome Profiler Human Phospho-Kinase Array (decrease in 
phosphorylation marked in red; increase in phosphorylation marked in green). Each kinase 
is spotted in duplicate. Loading reference points at lower exposure for each membrane are 
shown in Supplementary Fig. 3B. Pixel densitometry analysis was expressed as fold 
change comparing the shFRα sample to corresponding shNT sample. (B) Cells were 
treated with board spectrum Src-family kinase inhibitor A-419259 to access the dose 
dependent inhibition of cellular growth. Half-maximal inhibitory concentration (IC50) doses 
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were determined with MTT assay following 96 hr incubation. CAL51 incubated with A-
419259 had shown visible reduction in colony density over a three-week period, where the 
inhibitor was refreshed weekly, and decreased ERK activity after 4 hr of drug treatment. 
(C) A model depicting FRα-mediated regulation of cancer signaling and as folate 
transporter for cell growth and survival. (D) Viability assessment of FRα-targeting MOv18-
IgG1-coupled inhibitor ADC-treated CAL51 cells compared with MOv18-IgG1- and A-
419259- treated cells. Data are means ± SEM from N = 3 independent experiments. (E) 
Growth curves and weight measurements of resected CAL51 tumors (N=10 mice per 
treatment group) treated with a single-dose of ADC (7.5mg/kg), MOv18-IgG1 (7.5mg/kg), 
A-419259 (5 mg/kg) or PBS. * P < 0.05; ** P < 0.005; *** P < 0.0005, by two-tailed 
unpaired t-test. 
 
Figure 5. MOv18-IgG1 antibody induces immunotherapeutic tumor cell killing 
(A) Fluorescent images of the live cell cytotoxicity assay. Live CFSE-labelled CAL51 tumor 
cells (green) were incubated for 24 hr with MOv18-IgG1 or isotype antibody and PBMC 
(stained with CellTracker Blue dye). Incorporation of ethidium homodimer-1 is depicted as 
red fluorescence into damaged cells, was observed. (B) FFPE cell pellets of six breast 
cancer cell lines (CAL51, T47D, HDQ-P1, SKBR3, MDA-MB-231 and HCC1428) were cut 
and stained for evaluation of FRα expression. Breast cancer cells were treated with 5 
μg/ml MOv18-IgG1, or with isotype-matched control antibody. Human U937 monocytic 
cells were added to the tumor cells and incubated for 3 hr at 37oC followed by the flow 
cytometry-based tumor cell killing assay to determine the levels of ADCC and ADCP of 
cancer cells (N = 3). (C) Healthy volunteer PBMCs (N = 8), and TNBC patient PBMCs (N = 
9) were also used, results were illustrated as total % tumor cell killing and as separated 
ADCC (black) and ADCP (grey). MOv18-IgG1 appeared to induce  ADCP-biased anti-
tumor effects. All the data represent the mean ± SEM values of three independent 
experiments. * P < 0.05; ** P < 0.005; *** P < 0.0005, by two-tailed unpaired t-test.  
 
Figure 6. Restriction of orthotopic tumor growth in vivo 
(A) IHC evaluation of FRα expression in paraffin-embedded CAL51 xenograft tumor 
specimens. (B) Tumor engraftment of human immune cells were confirmed by anti-human 
CD45 IHC staining in tissue sections. (C) Growth curves and weight measurements of 
resected CAL51 tumors of the partly immuno-humanized mice treated with 5 or 10 mg/kg 
MOv18-IgG1 antibodies. (D) IHC evaluation of FRα expression in a TMA of 26 PDTX 
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models. Representative images showing no FRα expression in KCL005 and 100% positive 
FRα staining in WHIM02, with 43.2% of the TNBC PDTX models (N = 26) shown to be 
positive of FRα expression. (E) Tumor engraftment of human immune cells was confirmed 
by anti-human CD45 IHC staining. (F) Growth curves and weight measurements of 
resected WHIM02 PDTX tumors of the partly-immuno-humanized mice treated with 10 
mg/kg MOv18-IgG1. (G) Flow cytometric analyses demonstrating engraftment of CD45+ 
human immune cells in the WHIM02 PDTX model, and infiltrating immune cell populations 
of potential effector cells (human macrophages and NK cells). Data are means ± SEM * P 
< 0.05; ** P < 0.005; *** P < 0.0005, by two-tailed unpaired t-test. 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
 Published OnlineFirst August 1, 2018.Clin Cancer Res 
  
Anthony Cheung, James W. Opzoomer, Kristina M Ilieva, et al. 
  
Restrict the Growth of Triple Negative Breast Cancer
Anti-Folate Receptor alpha-directed Antibody Therapies
  
Updated version
  
 10.1158/1078-0432.CCR-18-0652doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://clincancerres.aacrjournals.org/content/suppl/2018/08/01/1078-0432.CCR-18-0652.DC1
Access the most recent supplemental material at:
  
Manuscript
Author
been edited. 
Author manuscripts have been peer reviewed and accepted for publication but have not yet
  
  
  
  
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
Rightslink site. 
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2018/08/01/1078-0432.CCR-18-0652
To request permission to re-use all or part of this article, use this link
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0652 
